Unedited news and product information from vendors.
Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
Oct 11, 2007 (06:10 AM EDT)
MOUNTAIN VIEW, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Daniel Weiner, Ph.D., senior vice president and chief technology officer, has been invited to speak to U.S. and Japanese biopharmaceutical executives attending a session on research and development productivity hosted by the New York Pharma Forum (NYPF), to be held in New York City, October 15, 2007.
Dr. Weiner's presentation will discuss the technical, organizational and process changes needed to reach the goals of the FDA's Critical Path Initiative for improving drug development productivity, including opportunities for the adoption of quantitative drug-disease modeling and simulation. Dr. Weiner will join other industry experts as part of the NYPF program entitled "R&D Productivity: Are There Winning Strategies?" The session will also offer a forum for interdisciplinary discussion on areas of opportunity in the drug development and approval process.
"Pharsight has built a strong reputation for providing critical solutions that increase productivity in the drug development industry," said Shawn O'Connor, president, chief executive officer, and chairman of Pharsight. "Through our strategic consulting services and growing family of software products, we have successfully collaborated with global drug developers to incorporate modeling and simulation into their development processes. These collaborations have yielded a number of success stories, ranging from increased efficiencies and more confident decision-making to better resource management. Pharsight is pleased to participate at this NYPF event, and to offer its perspectives on opportunities, challenges and supporting technical infrastructure to enable critical path clinical research in Japan and globally."
The New York Pharma Forum is a non-profit organization that provides U.S. and Japanese biopharmaceutical company executives with access to critical information on business, policy and technology issues that impact the global healthcare industry, with a focus on Japan. Additional information can be found at http://www.nypharmaforum.org .
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Forward Looking Statements
The statements in this press release related to the performance and benefits of Pharsight products and services are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations and customers may not perceive the benefits of Pharsight software products and services to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on August 13, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trade marks of their respective companies or organizations.
CONTACT: investors, Douglas Sherk, +1-415-896-6820, or JenniferBeugelmans, +1-646-201-5447, or media, Jen Saunders, +1-646-201-5431, allof EVC Group, for Pharsight Corporation
Web site: http://www.pharsight.com/ http://www.nypharmaforum.org/